Related Experiment Video
Updated: May 17, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
CPP-conjugated anti-apoptotic peptides as therapeutic tools of ischemia-reperfusion injuries
Prisca Boisguerin1, Jean-Michel Giorgi, Stéphanie Barrère-Lemaire
1UMR 5235 CNRS, Universite Montpellier 2, Place Eugene Bataillon, 34095 Montpellier, France. prisca.boisguerin@univ-montp2.fr
Insights
Inhibitory peptides targeting the mitochondrial apoptotic pathway show promise in limiting infarct size after acute myocardial infarction (AMI). This approach may prevent heart failure and improve survival, offering a novel therapeutic strategy.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biotechnology
Background:
- Acute myocardial infarction (AMI) is a leading cause of cardiovascular mortality worldwide.
- Infarct size significantly impacts myocardial recovery and post-AMI survival.
- Ischemia-reperfusion (IR) injury, a consequence of reperfusion therapy, can cause myocyte cell death.
Purpose of the Study:
- To investigate the potential of inhibitory peptides in limiting infarct size and protecting against IR injury.
- To explore the use of BH4 peptide as a cardioprotective agent in a murine model of AMI.
- To assess the adaptability of peptidic strategies for preventing apoptosis in other conditions like stroke and organ transplantation.
Main Methods:
- Utilized a known BH4 peptidic inhibitor of the mitochondrial apoptotic pathway.
- Administered the peptide via a single bolus of intravenous injection.
- Evaluated cardioprotective properties in a murine model of acute myocardial infarction.
Main Results:
- The BH4 peptide demonstrated cardioprotective properties in the studied murine model.
- The peptide limited infarct size and reduced myocyte cell death associated with AMI and IR injury.
- Peptide-based strategies showed potential for therapeutic intervention in cardiovascular diseases.
Conclusions:
- Peptidic inhibitors targeting the mitochondrial apoptotic pathway represent a promising strategy for limiting infarct size in AMI.
- This approach offers potential for preventing post-ischemic heart failure and improving patient survival.
- Similar peptidic strategies may be applicable to other conditions involving cellular apoptosis, such as stroke and organ transplantation.
Abstract:
Acute myocardial infarction (AMI) is a frequent and disabling disease, which is the first cause of cardiovascular mortality worldwide. Infarct size is a major determinant of myocardial functional recovery and mortality after AMI. Limitation of infarct size thus appears as an appropriate strategy to prevent post-ischemic heart failure and improve survival. Reperfusion is the only treatment recommended to reduce infarct size but despite obvious benefits, it may also have deleterious effects called ischemia-reperfusion (IR) injury including myocyte cell death. Proteins involved in the apoptosis cascade generally interact over large surfaces lacking well-defined pockets. Therefore, inhibitory peptides are optimal biomolecules to target these large protein surfaces, they are often more selective to their target than conventional small organic molecules, and they can be tailored for optimal affinity or desired metabolic property. Since peptides do not cross freely biological membranes, they are generally administered in association with cell penetrating peptides (CPPs) and with homing peptides (HPs) for selective organs or tissues targeting. As a first approach in vivo, we made use of the already known BH4 peptidic inhibitor of the mitochondrial apoptotic pathway, which showed cardioprotective properties in a murine model of AMI after a single bolus of intravenous administration. More importantly, similar peptidic strategies and tools are likely to be adaptable to many other situations in which cells have to be protected from apoptosis such as stroke or organ transplantation.
Related Concept Videos
01:17The Extrinsic Apoptotic Pathway
01:22Cellular Injury V: Apoptosis and Autophagy
01:31The Intrinsic Apoptotic Pathway